the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2019

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Pheochromocytoma
Interventions
DRUG

Dexmedetomidine

which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7\&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient

DRUG

General anesthetic

1\) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]

Trial Locations (1)

11796

Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo

All Listed Sponsors
lead

National Cancer Institute, Egypt

OTHER

NCT04320589 - the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma | Biotech Hunter | Biotech Hunter